

Neuroleptic Malignant Syndrome (NMS)

Background

Neuroleptic Malignant Syndrome (NMS) is a rare, acute and life threatening disorder of thermoregulation and neuromotor control. It is characterised by muscle rigidity, hyperthermia, altered consciousness and autonomic dysfunction through dopamine blockage following exposure to antipsychotic medication. It can range from mild with few signs and symptoms to an acute, severe syndrome that should be considered a medical emergency.¹ NMS generally develops within the first 2 weeks of an antipsychotic drug being initiated or after a change of dose.²

Incidence

Incidence of NMS is difficult to estimate as antipsychotic use has changed over time and awareness of the condition has increased. Incidence rates have decreased from 3% since it was first described in 1960 to around 0.01%-0.02% in patients treated with antipsychotics.²

Aetiology

The exact cause of NMS is unknown, but it is likely primarily related to central inhibition of dopaminergic transmission giving rise to autonomic instability and dysregulation.^{3,4} All antipsychotics, both first generation (FGAs) and second generation (SGAs) can cause NMS at any dose, although it is more likely with high dose, rapid dose escalation and first generation antipsychotics (FGAs).^{1,5} Neurotransmitter depletion occurs with FGA & SGA treatment and abrupt withdrawal of any dopamine agonists such as anti-Parkinson's agents.^{5,6}

The concurrent use of other medications which can affect dopamine concentrations (e.g. tricyclic antidepressants, selective serotonin reuptake inhibitors, domperidone, metoclopramide and lithium) have also been implicated.⁶ Combinations of antipsychotics with SSRIs or cholinesterase inhibitors may increase the risk of NMS; NMS-type syndromes induced by SGA/SSRI combinations may share their symptoms and pathogenesis with serotonin syndrome.¹ Conditions where central dopamine handling is affected can also predispose individuals to the syndrome, such as Parkinson's Disease or Wilson's disease.⁷

Summary of risk factors^{1,5,7}

Strong	Weak	Other
High potency FGAs	Older age	Abrupt withdrawal of anticholinergic agents
Recent or rapid dose increase	Pre-existing agitation	Organic brain disease
Antipsychotic polypharmacy	Male gender	Alcoholism
Intramuscular administration	Pre-existing dehydration	Parkinson's disease or Wilson's disease
Abrupt withdrawal of dopaminergic drugs	Exposure to other dopamine antagonists e.g. metoclopramide, lithium, certain antidepressants	Hyperthyroidism
Structural brain abnormality	Catatonia	Younger age

Diagnosis of NMS

The “classic” picture of NMS consists of a tetrad of symptoms: altered mental state, fever, extrapyramidal symptoms, and autonomic instability, although there can be a significant heterogeneity in the presentation.⁸ SGA-induced NMS may present without some (if not all) of these symptoms and there have been ‘atypical’ NMS cases where hyperthermia and muscle rigidity has developed either much slower or been completely absent.^{9,10} It is therefore paramount that all possible symptoms are considered (see table 1) when making a diagnosis.²

Altered Mental State	Hyperthermia	Autonomic Instability	Muscle Rigidity
Confusion	Temperatures >38.5°C	Fluctuating Blood Pressure	Creatinine Kinase markedly raised (>200 – 100,000 IU/L)
Delirium		Tachycardia	Extrapyramidal symptoms (Muscle stiffness)
Stupor		Excessive Sweating (Diaphoresis)	Trismus (jaw contraction)
Coma		Tachypnoea	‘Lead pipe’ rigidity
Grand mal seizures		Excessive Saliva Production (sialorrhea)	Rhabdomyolysis
Drowsiness		High arterial pressure	Opisthotonus (spinal contraction)
		Incontinence	Babinski’s sign (abnormal flexion of the toes)
			Chorea

Table 1: Groups of symptoms and signs of Neuroleptic Malignant Syndrome.

Differential diagnoses^{2,7}

Although a positive diagnosis is primarily symptom-based, NMS can mirror other conditions with little variation in presentation, and so these must be excluded before a definitive diagnosis is made (Table 2).

Laboratory findings^{1,2,7}

- Raised creatinine kinase (CK) at least four times upper limit of normal (can be asymptomatic¹)
- Abnormal LFTs
- Leucocytosis
- ECG abnormalities
- Electrolyte disturbances may also be present.

Temperatures above 40°C or renal failure secondary to rhabdomyolysis are indicators of **severe NMS** and are associated with a poorer prognosis and **urgent** medical attention is required. Further complications can include seizures, disseminated intravascular coagulation, respiratory failure, and aspiration pneumonia.^{8,11}

Differential diagnosis	Distinguishing features
Serotonin syndrome	Rapid onset after administration of a serotonergic drug, hyperreflexia, clonus, diarrhoea. (See SS guideline) <i>*hyperlink*</i>
Malignant hyperthermia	Usually after exposure to anaesthetics or depolarising muscle relaxants in genetically susceptible people; rapid onset, trismus (lockjaw)
Catatonia	Withdrawal, predominance of motor abnormalities, absence of hyperthermia, gradual evolution of presentation
Infection/sepsis	CNS or systemic signs and symptoms of infection
Heat stroke	Rapid onset, occurs during prolonged elevations in ambient temperatures; diaphoresis; muscle rigidity usually not present
Toxicity/overdose of other drugs e.g MAOIs, lithium	
Drug abuse/adverse reactions e.g. cocaine, amphetamines, CNS stimulants	History of drug abuse, overdose symptoms
Alcohol or sedative withdrawal	History of alcohol or sedative abuse
Metabolic conditions e.g. dehydration, hyponatraemia, hypokalaemia	Signs and symptoms of dehydration, abnormal U&Es

Table 2: Differential diagnosis

Treatment

The first step of treatment is to immediately withdraw **all potential** causative medicines. Subsequent management depends on the patient's presentation:

- Correct dehydration and hyperthermia
- Monitor temperature, pulse and blood pressure
- Sedate with benzodiazepines as necessary
- Measure WCC, U&Es, LFTs and CK
- In case of a medical emergency, transfer patient to acute medical care
- Treat acute symptoms: dantrolene, a muscle relaxant and/or bromocriptine, a dopaminergic agent and/or artificial ventilation may be required¹

Reintroduction of Antipsychotics

- Risk of recurrence of NMS can be as high as 30%¹²
- Allow symptoms to **completely** resolve before re-introducing antipsychotic, leave a gap of at least 2 weeks and avoid causative agent
- Establish if any there is any previous history of similar reaction

- Document NMS and causative agent within clinical notes as an adverse drug reaction
- Document clearly indications for antipsychotics
- Reduce any modifiable risk factors
- Choose an antipsychotic structurally unrelated to the causative agent or a drug with low dopamine affinity (quetiapine or clozapine)
- Avoid depot/LAI antipsychotic preparations and high potency FGAs
- Begin with a low dose and titrated slowly with close monitoring of physical and biochemical parameters e.g. temperature, BP, pulse, muscle tone, and CK

KEY SUMMARY

- **NMS is a rare but potentially fatal adverse reaction, most commonly seen with antipsychotic agents**
- **SGAs may have a lower incidence of NMS than FGAs**
- **Combinations of antipsychotics or antipsychotics with lithium or antidepressants may increase the risk of NMS**
- **Rarely associated with withdrawal or reduction of dose of dopamine agonists and use of metoclopramide and domperidone**
- **Symptoms include hyperthermia, autonomic instability, altered consciousness and muscle rigidity**
- **Laboratory findings include elevated CK, leucocytosis and impaired LFTs**
- **NMS is a diagnosis of exclusion, so differential diagnoses must be ruled out**

If NMS is suspected, discuss with senior colleagues and if clinically unwell, refer to acute hospital.

Reintroduction of all antipsychotics should only be initiated by senior medical staff.

References

1. Taylor D *et al*. Maudsley's Prescribing Guidelines in Psychiatry. Wiley 2018; **13**: 104-5.
2. UKMi Medicines Q&As. What is Neuroleptic Malignant Syndrome? February 2014. Q&A 309.3 www.evidence.nhs.uk Accessed online 27.12.18
3. Adnet P, Lestavel P, and Krivosic-Horber R. Neuroleptic Malignant Syndrome. British Journal of Anaesthesia. 2000; **85**(1): 129-135.
4. Maule E. Management of Neuroleptic Malignant Syndrome. Clinical Pharmacy. 2009; **1**(7): 203-205.
5. UKMi Medicines Q&As. What Drugs can Cause Neuroleptic Malignant Syndrome? September 2017. www.evidence.nhs.uk Accessed online 27.12.18.
6. Troller JN, Chen X, Sachdev PS. Neuroleptic Malignant Syndrome Associated with Atypical Antipsychotic Drugs. 2009; **23** (6): 477-492.
7. BMJ Best Practice. Neuroleptic Malignant Syndrome. Jan 2018 <https://bestpractice.bmj.com> Accessed online 27.12.2018.

8. Wargo KA, Gupta R. Neuroleptic malignant syndrome: no longer exclusively a "neuroleptic" phenomenon. *J. Pharm. Technol.* 2005; **21**: 262-270.
9. Picard *et al.* 2008. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. *Pharmacotherapy* 2008; **28**: 530-535.
10. Belvederi Murri *et al.* Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. *Drugs R. D.* 2015; **15**: 45-62.
11. Strawn JR *et al.* Neuroleptic malignant syndrome. *Am. J. Psychiatry.* 2007; **164** (6): 870-876.
12. Caroff SN, Mann SC. Neuroleptic malignant syndrome. *Medical Clinics of North America, Contemporary Clinical Neurology* 1993; **77**: 185–202.